Ballicules.com

Doxazosin

CARDURA

What it isAlpha-1 antagonist; benign prostatic hyperplasia and resistant hypertension.

Why this oneWorse heart-failure outcomes than chlorthalidone ended its first-line hypertension role; BPH is now the more defensible use.

What limits itFirst-dose orthostatic hypotension — start at night. Nonuroselective blockade causes more hypotension than tamsulosin.

FDA-approved for

Off-label

FDA label

FDA dosingPopulationStartTargetMax
Benign prostatic hyperplasiaAdults1 mg QD2–8 mg QD8 mg QD
HypertensionAdults1 mg QDtitrate to effect16 mg QD

Titration BPH: increase at 1–2 week intervals.

Renal Undefined

Hepatic Not recommended in severe (Child-Pugh C); monitor BP/hypotension in mild–moderate (A/B)

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Limited data insufficient to assess risk; untreated hypertension carries maternal risk

Lactation Undefined

NO BOXED WARNINGS

Principal riskFirst-dose orthostatic hypotension

Cost, est. cash$5–$150/month

Generic entry2000

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryUnknown / historical label unavailable

Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Mechanism of action: Doxazosin ballicule

Doxazosin ballicule: receptor binding, kinetics and half-life diagram

Open Doxazosin in the interactive console ↗

Memory aids: mascots and interaction avatars

Doxazosin CARDURA mascot mnemonic cartoon
“Carder, Dox A’s or sin”
Polka dots on pink → α1 blocker → syncope if titrated too quickly (hit the floor)
Doxazosin CYP3A4 substrate avatar
CYP3A4 substrate

Open Doxazosin in the interactive console ↗